Health
Anti-SARS-CoV-2 drug candidate enters phase I clinical trial – News-Medical.Net
DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of…
DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences enters its Phase I clinical trial in the United States on March 15.
DC402234, a peptidomimetic compound, was designed and synthesized through analyzing the crystal structure of the coronaviruses Mpro.
Researchers found that DC402234 exhibits effective inhibitory activity against SARS-CoV-2 Mpro with IC50 values of 0.053 ± 0.005 μM,…
-
Noosa News6 hours agoHow Lily Steele-Park took her rapist to court and won
-
General20 hours ago‘Potential’ hacker contacts Qantas over data breach
-
Business11 hours agoFord CEO makes stunning prediction about artificial intelligence
-
Business21 hours ago5 amazing ASX ETFs for Aussie investors in July